|1.||Figus, Michele: 1 article (01/2009)|
|2.||Fogagnolo, Paolo: 1 article (01/2009)|
|3.||Benelli, Umberto: 1 article (01/2009)|
|4.||Canovetti, Annalisa: 1 article (01/2009)|
|5.||Nardi, Marco: 1 article (01/2009)|
|6.||Theou, Katerina: 1 article (03/2005)|
|7.||Bitsios, Panos: 1 article (03/2005)|
|8.||Hourdaki, Eugenia: 1 article (03/2005)|
|9.||Grinakis, Vangelis: 1 article (03/2005)|
|10.||Giakoumaki, Stella G: 1 article (03/2005)|
12/01/2000 - "There is evidence that reaching normal pupil diameters after reversal of mydriasis by dapiprazole is a valid sign of restoration of traffic related functions."
12/01/2000 - "Before mydriasis and after reversal with dapiprazole traffic-related functions were evaluated (photopic visual acuity, mesopic vision, sensitivity to glare, colour vision, accommodation, visual field). "
08/01/1997 - "Dapiprazole HCL is currently available in the United States for reversal of diagnostic mydriasis. "
11/01/1991 - "The results showed a significant reversal of mydriasis by intraocular dapiprazole, especially with the 0.25% and 0.5% concentrations which did not differ significantly in effectiveness and safety."
09/01/1990 - "Effects of dapiprazole on the reversal of pharmacologically induced mydriasis."
|2.||Open-Angle Glaucoma (Glaucoma, Open Angle)
09/01/1996 - "The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma."
01/01/1996 - "Our results show that the introduction of dapiprazole in the therapy of pigmentary glaucoma may be useful in the long-term management of these patients. "
01/01/1996 - "In this investigation the authors studied the effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in patients affected with pigmentary glaucoma. "
01/01/1996 - "Effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in pigmentary glaucoma."
01/01/1996 - "Dapiprazole 0.5% eye drops were administered 3 times daily as adjunctive therapy to 16 pigmentary glaucoma patients in addition to timolol 0.5% eye drops twice daily. "
05/01/1994 - "All of our subjects exhibited conjunctival hyperemia after the administration of dapiprazole. "
10/01/1993 - "All of our subjects exhibited conjunctival hyperemia after the administration of dapiprazole. "
01/01/2009 - "Dapiprazole 0.25% had a miotic effect similar to that of brimonidine but produced many side effects including hyperemia and burning, which many patients said caused significant discomfort. "
12/01/1995 - "Validation was against an established photographic reference scale of ocular hyperemia and against the clinical pharmacologic effects of 0.5% dapiprazole hydrochloride, known to increase hyperemia, and 2.5% phenylephrine hydrochloride, known to decrease hyperemia. "
04/01/1989 - "The conjunctival hyperemia induced by dapiprazole was reversed by additional instillation of epinephrine. "
03/01/2005 - "In Experiment 1, dapiprazole caused significant miosis. "
11/01/1989 - "Dapiprazole produces miosis by blocking the alpha 1 receptors in the radial muscle of the iris; its intraocular effect has not yet been investigated. "
10/01/1996 - "Dapiprazole drops produced a Horner's miosis, but pupils were equally small after induction of anesthesia. "
03/01/2005 - "At the point of maximum dapiprazole-evoked miosis, the light reflex was elicited three times in each of three Safe blocks (no possibility of electric shock), alternating with three Threat blocks (possibility of electric shock). "
07/01/1995 - "Dapiprazole and pilocarpine together induced miosis significantly faster than each drug alone, showing additive effects. "
|5.||Angle-Closure Glaucoma (Glaucoma, Angle Closure)
01/01/1982 - "These results suggest a potential interest of dapiprazole in glaucoma, with particular reference to the topical treatment of angle-closure glaucoma."
07/01/1995 - "Co-administration of dapiprazole and pilocarpine at the end of the eye examination will induce fast pupillary constriction, which might be useful in preventing the development of an acute attack of angle-closure glaucoma in patients with anatomically narrow angles."
|4.||Ophthalmic Solutions (Eye Drops)
|7.||Adrenergic Antagonists (Antiadrenergic Agents)
|2.||Intraocular Lens Implantation
|4.||Intraocular Lenses (Intraocular Lens)